CURE Pharmaceutical to Acquire Sera Labs for $20 Million

SERB Pharmaceuticals Acquires Y-mAbs Therapeutics

September 16, 2025

Biotechnology

SERB Pharmaceuticals completed its acquisition of Y-mAbs Therapeutics following a tender offer and statutory merger, making Y-mAbs a wholly owned subsidiary and delisting it from Nasdaq. The deal adds Y-mAbs' antibody-based oncology assets — including Danyelza (naxitamab-gqgk) — to SERB's rare disease and rare oncology portfolio to expand its commercial capabilities in pediatric and rare cancers.

CV Sciences Acquires Extract Labs

November 21, 2024

Consumer Products

CV Sciences, Inc. entered into a definitive agreement to acquire Extract Labs, Inc., a manufacturer and distributor of premium cannabinoid products, for $400,000 in cash plus $1,000,000 in CV Sciences shares at closing. Additional contingent consideration of up to $600,000 in CV Sciences shares may be earned based on Extract Labs revenue targets post-closing, which is expected in Q1 2025.

Cresco Labs to Acquire Columbia Care in Definitive Transaction

July 8, 2022

Healthcare Services

Cresco Labs entered into a definitive arrangement agreement to acquire all of the issued and outstanding shares of Columbia Care. Shareholders of Columbia Care approved the plan of arrangement at a special meeting, and the transaction is expected to close in the fourth quarter of 2022 subject to customary conditions and approvals.

Item 9 Labs Corp. Acquires The Herbal Cure (Denver)

March 17, 2022

Retail

Item 9 Labs Corp. (OTCQX: INLB) signed an Asset Purchase Agreement to acquire The Herbal Cure, a Denver-based medicinal and recreational cannabis dispensary and cultivator. The acquisition — which includes a 5,000 sq ft facility with 3,500 sq ft of retail/corporate space and a separate 3,000 sq ft cultivation area — will be converted to Item 9’s Unity Rd. dispensary brand pending regulatory approvals; The Herbal Cure reported $5.4 million in 2021 revenue.

Laboratoires SERB (Charterhouse-backed) to acquire BTG Specialty Pharmaceuticals from Boston Scientific

December 1, 2020

Pharmaceuticals

Charterhouse Capital Partners–backed Laboratoires SERB has agreed to acquire BTG Specialty Pharmaceuticals from Boston Scientific. The deal expands SERB’s portfolio of emergency and critical‑care medicines (including CroFab, DigiFab and Voraxaze), strengthening its manufacturing capabilities and global commercial reach.

Curative Inc. Acquires KorvaLabs, Inc.

May 19, 2020

Healthcare Services

Curative Inc. has acquired KorvaLabs, a CLIA-certified and DEA-licensed analytical laboratory based in San Dimas, California, formalizing a partnership that supported Curative's manufacture and processing of its oral fluid COVID-19 test. The acquisition strengthens Curative's testing capacity — to date the organizations processed 245,371 tests together and were processing roughly 14,000 tests per day — and secures in-house manufacturing and processing capabilities.